Cara Therapeutics issues investor deck for pending merger with Tvardi (STAT3 fibrosis program)

Tvardi Therapeutics, Inc.

Merger with Tvardi Therapeutics (STAT3 inhibitor developer for fibrosis) announced Dec 17, 2024; closing conditions remain.
Investor presentation shared with potential investors outlines Tvardi's clinical pipeline and post-combination strategy.
No new financial terms disclosed; forward-looking statements caution on risks related to closing timing and regulatory submissions.
Tvardi focuses on oral small-molecule STAT3 therapies for fibrosis-driven diseases with significant unmet need.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.